enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM

enGene Therapeutics Inc.

56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.
All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.
Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.
No other significant proposals; no change in board composition or auditor.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2026-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 2 – Appointment and Remuneration of Auditor For Withhold Broker Non-Votes 56,180,287 16,015 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Philip Astley-Sparke 47,112,414 306,821 8,777,067 Ronald H.W. Cooper 47,329,848 89,387 8,777,067 Dr. William Grossman 47,408,163 11,072 8,777,067 Michael Heffernan 47,408,163 11,072 8,777,067

View on SEC.gov

Browse all shareholder votes →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-265830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.